Guruprasad Pattar, MD
Ophthalmology · Louisville, KYNPI 1689963589
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 36.7% of the total. Among ophthalmology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $233.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$13K
- Alcon$13K
- Alcon Research LLC$5K
- Argenx US, Inc.$3K
- Tarsus Pharmaceuticals, Inc.$381
- AbbVie$342
- plus $1K from 16 others
Across 148 payments — averaging $6518.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$422K
- Alcon Research LLC$344K
- Aerie Pharmaceuticals, Inc.$81K
- Oyster Point Pharma, Inc.$51K
- Argenx US, Inc.$24K
- Roche TCRC, Inc.$21K
- plus $22K from 3 others
What the payments were for
- Consulting fees$14,74841%
- Speaking & faculty fees$12,50035%
- Travel & lodging$4,65613%
- Food & beverage$3,77011%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 25 | $13,100 |
| Alcon | 23 | $12,797 |
| Alcon Research LLC | 9 | $5,404 |
| Argenx US, Inc. | 13 | $2,509 |
| Tarsus Pharmaceuticals, Inc. | 9 | $381 |
| AbbVie(2 entities) | 18 | $342 |
| Oyster Point Pharma, Inc. | 12 | $296 |
| Bausch & Lomb Americas Inc. | 8 | $210 |
| Novartis | 7 | $131 |
| Aerie Pharmaceuticals, Inc. | 7 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| Dompe US, Inc. | 3 | $86 |
| Ocular Therapeutix, Inc. | 4 | $66 |
| Harrow Eye, LLC | 2 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Coopervision Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Integra Lifesciences Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,739 in reported general payments places this provider in the 95th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 134 | $138,522 |
| RestasisCyclosporine | 97 | $96,488 |
| CequaCyclosporine | 66 | $38,737 |
| TyrvayaVarenicline Tartrate | 53 | $33,859 |
| LumiganBimatoprost | 40 | $21,926 |
| Cyclosporine | 24 | $15,867 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,746 |
| Prednisolone Acetate | 191 | $8,402 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $5,574 |
| Ketorolac Tromethamine | 239 | $5,388 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $5,206 |
| Fluorometholone | 51 | $3,248 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $2,596 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,238 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 42 | $1,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $210 | $151,268151 claims |
| AbbVieRestasis, Lumigan, Combigan | $342 | $123,988154 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $13,100 | $38,73766 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $296 | $33,85953 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $115 | $5,20616 claims |
| AlconSimbrinza | $12,797 | $2,23811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Louisville
- Jeremy ClarkLouisville$131K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Inder SingalLouisville$9K
- Rishi KumarLouisville$8K
- Frank BurnsLouisville$8K
- Steven BloomLouisville$6K
- Sharmini BalakrishnanLouisville$6K
- Sergei DmitrukLouisville$5K
- Lawrence TenkmanLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.